Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Obinutuzumab + RO6958688 + RO7122290 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Obinutuzumab | Gazyva | R7159|afutuzumab|GA101|GA-101|RO 5072759 | CD20 Antibody 24 | Gazyva (obinutuzumab) is a glycoengineered anti-CD20 antibody that binds to CD20 on B-cells, resulting in increased antibody-dependent cellular cytotoxicity and induction of apoptosis, and potentially leading to decreased growth of B-cell tumors (PMID: 20194898, PMID: 21220500). Gazyva (obinutuzumab) is FDA approved in combination with Ambochlorin (chlorambucil) for chronic lymphocytic leukemia and in combination with Treanda (bendamustine) or chemotherapy for follicular lymphoma (FDA.gov). |
RO6958688 | RG7802|Cibisatamab|CEA-TCB|RO-6958688 | CD3 Antibody 98 | RO6958688 (cibisatamab) is a bispecific antibody that binds to CD3 and human anti-carcinoembryonic antigen (CEA) simultaneously, which may lead to cytotoxic immune response against CEA-positive tumor cells (PMID: 30982469). | |
RO7122290 | RO 7122290|RO-7122290 | RO7122290 is a fusion protein consisting of a ligand of TNFRS9 fused to a Fab fragment targeting FAP, which may lead to activation of anti-tumor immune response against FAP-expressing tumor cells (Ann Oncol Sep 2020, 31 (Suppl 4), S707). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04826003 | Phase Ib/II | Obinutuzumab + RO6958688 + RO7122290 | Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment | Active, not recruiting | NLD | GBR | ESP | 2 |